RxDoctor Payments Data

Anthony Chung, MD

Internal Medicine · Pembroke Pines, FLNPI 1467912881

Payments from drug & device makers

$2,615in general payments, 2019–2025

Across 108 payments — averaging $24.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$616
  • Novo Nordisk$376
  • GSK$337
  • AbbVie$204
  • Pfizer$194
  • Medtronic$149
  • plus $739 from 18 others

What the payments were for

  • Food & beverage$2,59799%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,615 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$109,759
Medicare patients
203
Services billed
1,896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban140$126,340
OzempicSemaglutide80$110,044
TrulicityDulaglutide33$42,431
FarxigaDapagliflozin Propanediol36$40,881
JardianceEmpagliflozin32$38,111
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$27,642
XareltoRivaroxaban17$27,344
JanuviaSitagliptin Phosphate22$26,458
InvokanaCanagliflozin11$18,700
MyrbetriqMirabegron12$14,359
Atorvastatin Calcium704$9,893
Tresiba Flextouch U-100Insulin Degludec21$8,510
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,783
Atrovent HfaIpratropium Bromide14$6,489
Levothyroxine Sodium303$3,839

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$194$126,340140 claims
Novo NordiskOzempic$376$110,04480 claims
AstraZenecaFarxiga, Breztri Aerosphere$616$47,66447 claims
Lilly USA, LLCTrulicity$97$42,43133 claims
Boehringer IngelheimJardiance$17$38,11132 claims
GSKTrelegy Ellipta$337$27,64227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →